Results 181 to 190 of about 4,101 (234)

Triplet regimens for frontline treatment of CLL-Great company or just a crowd? [PDF]

Hemasphere
McKeague S, Seymour JF.
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells. [PDF]

Neurol Neuroimmunol Neuroinflamm
Dybowski S, Thode J, Freier M, Saberi D, Nessler S, Geladaris A, Häusser-Kinzel S, Ringelstein M, Torke S, Weber MS.   +9 more
europepmc   +1 more source

608 | CLINICAL CHARACTERISTICS AND INITIAL TREATMENT PATTERNS OF MANTLE CELL LYMPHOMA PATIENTS IN THE BTKi ERA: A REAL‐WORLD STUDY [PDF]

龙. 何, 婉. 陈, 开. 盛, 前 程, 陈. 王, 海. 黄   +5 more
openalex   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors. [PDF]

Front Pharmacol
Zhang Y, Fu H, Kang X, Qiu Z, Yan H, He Q, Yang B, Xu Z, Luo P.   +8 more
europepmc   +1 more source

The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study. [PDF]

Hemasphere
Quaglia FM, Arcari A, Morello L, Marcheselli L, Tucci A, Pagani C, Bozzoli V, Scapinello G, Piazza F, Zilioli VR, Muzi C, Puccini B, Sordi B, Tisi MC, Rampi N, Castellino A, Usai SV, Paternoster J, Cencini E, Ferrero S, Consoli C, Basso M, Lucchini E, Pennese E, Nizzoli ME, Spina M, Pezzullo L, Candia MS, Tavarozzi R, Krampera M, Visco C.   +30 more
europepmc   +1 more source

Awareness and real-world practices in chronic lymphocytic leukemia: insights from a nationwide survey of Korean hematologists. [PDF]

Blood Res
Cha S, Kim SJ, Yoo KH, Park E, Byun JM.
europepmc   +1 more source

Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review. [PDF]

Open Forum Infect Dis
Aparicio-Minguijón E, López-Muñoz N, Boán J, Pérez-Jacoiste Asín MA, de la Serna J, Pérez-Ayala A, Enguita AB, Rodríguez-Goncer I, Fernández-Ruiz M.   +8 more
europepmc   +1 more source

Indirect comparison of continuous and time‑limited BTKi–venetoclax in TP53 ‑wild‑type CLL: does IGHV still matter?

S Molica, Diana Giannarelli, David Allsup   +2 more
openalex   +2 more sources

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence. [PDF]

Front Oncol
Dirican CD, Ajayi F, Al Mardini A, Crocete Aloysia Fernandes B, Sofia A, Gondhi V, Shaaban H, Maroules M.   +7 more
europepmc   +1 more source